Advertisement
Advertisement

TheBody.com/TheBodyPRO.com cover the XIX International AIDS Conference (AIDS 2012)

Medical News

Gilead HIV Drug as Good as Merck's Isentress: Study

August 2, 2012

Gilead Sciences Inc. said elvitegravir, a component in its four-drug HIV treatment Quad, showed similar efficacy and tolerability compared to Merck & Co.'s Isentress in a two-year trial.

The results of the study in previously treated HIV patients were presented at the 19th International AIDS Conference. In the late-stage clinical trial, elvitegravir met the primary clinical goal of being non-inferior to Isentress, the researchers said.

"As patients are living with HIV longer, there is a continued need for new treatment options, particularly those that are effective against strains of the virus that have developed resistance to currently available therapies," said Dr. Richard Elion, lead investigator.

US and European health regulators are reviewing elvitegravir for approval. The US Food and Drug Administration is expected to make an approval decision on Quad in August.

Both once-daily elvitegravir and twice-daily Isentress (raltegravir) are integrase inhibitors: They interfere with HIV's replication by thwarting its ability to integrate into the genetic material of human cells.

Both treatment groups had similar rates of adverse side effects, side effect-related discontinuations, and drug resistance development; however, reports of diarrhea were more common among study subjects taking elvitegravir (13 percent vs. 8 percent).

Back to other news for August 2012

Adapted from:
Reuters
07.24.2012; Bill Berkrot




This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 


No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement